Press releases
- Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
- Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
- Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
- Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
- Satellos to Present at Upcoming Virtual Investor Conferences in March and April
- Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
- Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
More ▼
Key statistics
On Friday, Satellos Bioscience Inc (0ITA:FRA) closed at 0.31, 84.52% above the 52 week low of 0.168 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.31 |
---|---|
High | 0.31 |
Low | 0.31 |
Bid | 0.342 |
Offer | 0.368 |
Previous close | 0.298 |
Average volume | 0.00 |
---|---|
Shares outstanding | 112.79m |
Free float | 98.73m |
P/E (TTM) | -- |
Market cap | 57.52m CAD |
EPS (TTM) | -0.1718 CAD |
Data delayed at least 15 minutes, as of May 31 2024 07:05 BST.
More ▼